Related Experiment Video
Updated: Jun 21, 2026
08:19
Solid Lipid Nanoparticles (SLNs) for Intracellular Targeting Applications
Published on: November 17, 2015
Nuclisome: a novel concept for radionuclide therapy using targeting liposomes
Amelie Fondell1, Katarina Edwards, Ludger M Ickenstein
1Department of Oncology, Radiology, and Clinical Immunology, Unit of Biomedical Radiation Sciences, Rudbeck Laboratory, Uppsala University, 75185 Uppsala, Sweden.
European Journal of Nuclear Medicine and Molecular Imaging
|August 8, 2009
Summary
This study introduces Nuclisome-particles, a novel liposome delivery system for Iodine-125 (125I) to target cancer cell nuclei. This targeted approach shows significant potential for treating metastasizing cancers.
Area of Science:
- Nuclear medicine
- Nanotechnology
- Oncology
Background:
- Auger-electron emitters like Iodine-125 (125I) show therapeutic promise for cancer treatment.
- The efficacy of Auger-electron emitters depends on their proximity to DNA.
- A new strategy is needed to effectively deliver these agents to cancer cell nuclei.
Purpose of the Study:
- To develop and evaluate a two-step targeting strategy for delivering 125I into cancer cell nuclei.
- To utilize PEG-stabilized tumor-cell targeting liposomes (Nuclisome-particles) for this purpose.
Main Methods:
- Liposomes were loaded with 125I-Comp1, a daunorubicin derivative.
- Epidermal growth factor (EGF) was used to target the epidermal growth factor receptor (EGFR) on tumor cells.
- An ex vivo system using a Chandler loop assessed targeting of circulating tumor cells.
Main Results:
- Nuclisome-particles demonstrated receptor-specific uptake in U-343MGaCl2:6 tumor cells.
- Targeted cells showed radiolabeled drug co-localization with cell nuclei.
- Nuclisome-particles were significantly more effective (up to 10^5 times) in cell killing than doxorubicin-loaded liposomes.
Conclusions:
- The developed two-step targeting strategy effectively delivers 125I to tumor cell nuclei.
- This approach shows promise as an effective therapy for metastasizing cancers in the bloodstream.
